Sarcoma Oncology Center

Santa Monica, California 940403

10 studies enrolling now · 85 studies all time

What they study most

Acute Promyelocytic Leukemia, Adamantinomatous Craniopharyngioma, Adult Angiosarcoma, Adult Solid Tumor, Advanced Angiosarcoma, Advanced Cancer, Advanced Sarcoma, Advanced Soft Tissue Sarcoma, Advanced Soft-tissue Sarcoma, Advanced Solid Neoplasm, Advanced Solid Tumor, Advanced Solid Tumors

Studies at this site

• Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations — Recruiting now
• FOG-001 in Locally Advanced or Metastatic Solid Tumors — Recruiting now
• Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors — Recruiting now
• A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors — Recruiting now
• Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas — Recruiting now
• Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors — Recruiting now
• Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) — Recruiting now
• Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors — Recruiting now
• Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma — Recruiting now
• A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer — Recruiting now
• A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine — Running, not enrolling
• A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma — Running, not enrolling
• Study of INBRX-109 in Conventional Chondrosarcoma — Running, not enrolling
• Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) — Running, not enrolling
• INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC — Running, not enrolling
• This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) — Completed
• Study of DF6215 in Patients With Advanced Solid Tumors — Completed
• Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma — Completed
• Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor — Completed
• A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) — Completed
• Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer — Stopped early
• Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors — Running, not enrolling
• Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma — Completed
• ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer — Completed
• Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors — Stopped early
• A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors — Running, not enrolling
• A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) — Running, not enrolling
• Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors — Completed
• Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma — Completed
• Safety Study of Sterile Compound C31510 for Injection to Subjects With Solid Tumors — Completed
• A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response — Completed
• Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy — Completed
• Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases — Completed
• Phase 3 Study to Treat Patients With Soft Tissue Sarcomas — Completed
• Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer — Completed
• Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma — Completed
• Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma — Completed
• Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma — Completed
• Camsirubicin + Pegfilgrastim to Determine MTD in ASTS — Stopped early
• A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma — Status unconfirmed
• Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers — Stopped early
• Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) — Stopped early
• YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma — Status unconfirmed
• A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) — Status unconfirmed
• A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors — Completed
• Selinexor in Advanced Liposarcoma — Completed
• A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g) — Stopped early
• (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors — Completed
• Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma — Completed
• Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors — Completed